Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents - PubMed (original) (raw)
Review
Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents
Rikki N Waterhouse. Mol Imaging Biol. 2003 Nov-Dec.
Abstract
Compound lipophilicity is a fundamental physicochemical property that plays a pivotal role in the absorption, distribution, metabolism, and elimination (ADME) of therapeutic drugs. Lipophilicity is expressed in several different ways, including terms such as Log P, clogP, delta Log P, and Log D. Often a parabolic relationship exists between measured lipophilicity and in vivo brain penetration of drugs, where those moderate in lipophilicity often exhibit highest uptake. Reduced brain extraction of more lipophilic compounds is associated with increased non-specific binding to plasma proteins. More lipophilic compounds can also be more vulnerable to P450 metabolism, leading to faster clearance. Very polar compounds normally exhibit high water solubility, fast clearance through the kidneys, and often contain ionizable functional groups that limit blood-brain barrier (BBB) penetration. The brain penetration and specific to non-specific binding ratios exhibited in vivo by positron emission tomography (PET) and single photon emission computed tomography (SPECT) radiotracers involves a complex interplay between many critical factors, including lipophilicity, receptor affinity, metabolism, molecular size and shape, ionization potential, and specific binding to BBB efflux pumps or binding sites on albumin or other plasma proteins. This paper explores situations in which lipophilicity is a good predictor of BBB penetration, as well as those where this correlation is poor. The more commonly used methods for measuring lipophilicity are presented, and the various terms often found in the literature outlined. An attempt is made to describe how this information can be used in optimizing the development of PET and SPECT tracers that target the central nervous system (CNS).
Similar articles
- Radiopharmaceuticals for brain imaging.
Saha GB, MacIntyre WJ, Go RT. Saha GB, et al. Semin Nucl Med. 1994 Oct;24(4):324-49. doi: 10.1016/s0001-2998(05)80022-4. Semin Nucl Med. 1994. PMID: 7817203 Review. - Validation of in vitro cell-based human blood-brain barrier model using clinical positron emission tomography radioligands to predict in vivo human brain penetration.
Mabondzo A, Bottlaender M, Guyot AC, Tsaouin K, Deverre JR, Balimane PV. Mabondzo A, et al. Mol Pharm. 2010 Oct 4;7(5):1805-15. doi: 10.1021/mp1002366. Epub 2010 Sep 15. Mol Pharm. 2010. PMID: 20795735 - PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS.
Elsinga PH, Hendrikse NH, Bart J, Vaalburg W, van Waarde A. Elsinga PH, et al. Curr Pharm Des. 2004;10(13):1493-503. doi: 10.2174/1381612043384736. Curr Pharm Des. 2004. PMID: 15134571 Review. - Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists.
Rowley M, Kulagowski JJ, Watt AP, Rathbone D, Stevenson GI, Carling RW, Baker R, Marshall GR, Kemp JA, Foster AC, Grimwood S, Hargreaves R, Hurley C, Saywell KL, Tricklebank MD, Leeson PD. Rowley M, et al. J Med Chem. 1997 Dec 5;40(25):4053-68. doi: 10.1021/jm970417o. J Med Chem. 1997. PMID: 9406596 - Immobilized Artificial Membrane HPLC Derived Parameters vs PAMPA-BBB Data in Estimating in Situ Measured Blood-Brain Barrier Permeation of Drugs.
Grumetto L, Russo G, Barbato F. Grumetto L, et al. Mol Pharm. 2016 Aug 1;13(8):2808-16. doi: 10.1021/acs.molpharmaceut.6b00397. Epub 2016 Jul 14. Mol Pharm. 2016. PMID: 27377191
Cited by
- Prediction of the First-Pass Metabolism of a Drug After Oral Intake Based on Structural Parameters and Physicochemical Properties.
Hosseini MAH, Alizadeh AA, Shayanfar A. Hosseini MAH, et al. Eur J Drug Metab Pharmacokinet. 2024 Jul;49(4):449-465. doi: 10.1007/s13318-024-00892-6. Epub 2024 May 11. Eur J Drug Metab Pharmacokinet. 2024. PMID: 38733548 - Evaluation of the Lipophilicity of Angularly Condensed Diquino- and Quinonaphthothiazines as Potential Candidates for New Drugs.
Klimoszek D, Jeleń M, Morak-Młodawska B, Dołowy M. Klimoszek D, et al. Molecules. 2024 Apr 8;29(7):1683. doi: 10.3390/molecules29071683. Molecules. 2024. PMID: 38611961 Free PMC article. - Advances in nanoprobes for molecular MRI of Alzheimer's disease.
Parekh P, Badachhape AA, Tanifum EA, Annapragada AV, Ghaghada KB. Parekh P, et al. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024 Mar-Apr;16(2):e1946. doi: 10.1002/wnan.1946. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024. PMID: 38426638 Review. - Intranasal Radioiodinated Ferulic Acid Polymeric Micelles as the First Nuclear Medicine Imaging Probe for ETRA Brain Receptor.
Fayez H, Selim A, Shamma R, Rashed H. Fayez H, et al. Curr Radiopharm. 2024;17(2):209-217. doi: 10.2174/0118744710269885231113070356. Curr Radiopharm. 2024. PMID: 38213167 - 99mTc(CO)3-labeled 1-(2-Pyridyl)piperazine derivatives as radioligands for 5-HT7 receptors.
Mardanshahi A, Vaseghi S, Hosseinimehr SJ, Abedi SM, Molavipordanjani S. Mardanshahi A, et al. Ann Nucl Med. 2024 Feb;38(2):139-153. doi: 10.1007/s12149-023-01885-2. Epub 2023 Nov 30. Ann Nucl Med. 2024. PMID: 38032496
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources